柔红霉素结合阿糖胞苷在急性髓系白血病患者中的应用效果  

Application effect of Daunorubicin combined with Arabinsyl cytosine in patients with acute myeloid leukemia

作　　者：彭志元 高陆 赵凌苇 刘水玉 石彬 任明强 PENG Zhiyuan;GAO Lu;ZHAO Lingwei;LIU Shuiyu;SHI Bin;REN Mingqiang(Department of Hematology,Affiliated Hospital of Zunyi Medical University,Guizhou Province,Zunyi563000,China;Department of Clinical Laboratory,Affiliated Hospital of Zunyi Medical University,Guizhou Province,Zunyi563000,China)

机构地区：[1]遵义医科大学附属医院血液内科,贵州遵义563000 [2]遵义医科大学附属医院检验科,贵州遵义563000

出　　处：《中国当代医药》2024年第27期46-49,共4页China Modern Medicine

摘　　要：目的评估柔红霉素(DNR)+阿糖胞苷(Ara-C)应用在急性髓系白血病(AML)患者中的效果。方法选取2020年1月至2023年12月遵义医科大学附属医院收治的80例AML患者作为研究对象,按照随机数字表法将其分为对照组(40例)与观察组(40例)。对照组患者采用DNR治疗,观察组患者采用DNR+Ara-C治疗。比较两组患者的临床有效率、免疫功能、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)、可溶性血管细胞黏附分子-1(sVCAM-1)、可溶性细胞间黏附分子-1(sICAM-1)、不良反应。结果观察组临床总有效率高于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后CD8^(+)、VEGF、bFGF、sVCAM-1、sICAM-1水平低于对照组,CD4^(+)、CD3^(+)水平高于对照组,差异有统计学意义(P<0.05)。两组的不良反应比较,差异无统计学意义(P>0.05)。结论AML患者采用DNR+Ara-C,可以降低VEGF、bFGF、sVCAM-1、sICAM-1,减轻免疫抑制,提高临床有效率,安全性好,有临床借鉴意义。Objective To evaluate the efficacy of Daunorubicin(DNR)+Arabinsyl cytosine(Ara-C)in patients with acute myeloid leukemia(AML).Methods A total of 80 AML patients admitted to the Affiliated Hospital of Zunyi Medical University from January 2020 to December 2023 were selected as the study objects,and they were divided into control group(40 cases)and observation group(40 cases)according to random number table method.Control group was treated with DNR,observation group was treated with DNR+Ara-C.The clinical effective rate,immune function,vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF),soluble vascular cell adhesion molecule-1(sVCAM-1),soluble intercellular adhesion molecule-1(sICAM-1)and adverse reactions were compared between the two groups.Results The total clinical effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD8^(+),VEGF,bFGF,sVCAM-1 and sICAM-1 in observation group were lower than those in control group,and the levels of CD4^(+)and CD3^(+)were higher than those in control group,with statistical significances(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion DNR+Ara-C in AML patients can reduce VEGF,bFGF,sVCAM-1,sICAM-1,alleviate immunosuppression,improve clinical efficiency,good safety,and have clinical reference significance.

关 键 词：柔红霉素 阿糖胞苷 急性髓系白血病 免疫功能 不良反应 

分 类 号：R733.71[医药卫生—肿瘤]